A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies.

Trial Profile

A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs MK 0752 (Primary)
  • Indications CNS cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Mar 2012 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Actual patients number is 33 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top